Aptevo Therapeutics (NASDAQ:APVO) Share Price Passes Below Fifty Day Moving Average – Here’s What Happened

Aptevo Therapeutics Inc. (NASDAQ:APVO) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $4.88 and traded as low as $4.67. Aptevo Therapeutics shares last traded at $4.67, with a volume of 16,520 shares.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 29th. Weiss Ratings upgraded Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Aptevo Therapeutics Stock Down 2.7%

The company’s 50-day moving average is $4.88 and its two-hundred day moving average is $8.06. The company has a market cap of $5.84 million, a P/E ratio of -0.02 and a beta of 1.68.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($6.41) EPS for the quarter, hitting the consensus estimate of ($6.41). On average, analysts anticipate that Aptevo Therapeutics Inc. will post -24.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.